Summit Therapeutics Inc [SMMT] stock is trading at $27.90, up 13.09%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SMMT shares have gain 18.90% over the last week, with a monthly amount glided 36.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on March 26, 2025, when Citigroup upgraded its rating to a Buy and also boosted its price target to $35 from $23. On March 12, 2025, Evercore ISI initiated with a Outperform rating and assigned a price target of $30 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $42 on February 28, 2025. Truist initiated its recommendation with a Buy and recommended $35 as its price target on January 08, 2025. Wells Fargo started tracking with a Overweight rating for this stock on December 11, 2024, and assigned it a price target of $30. In a note dated December 06, 2024, Jefferies initiated an Buy rating and provided a target price of $31 on this stock.
Summit Therapeutics Inc [SMMT] stock has fluctuated between $2.10 and $36.91 over the past year. Currently, Wall Street analysts expect the stock to reach $38.25 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $27.90 at the most recent close of the market. An investor can expect a potential return of 37.1% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.7 and Total Capital is -0.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.81 points at the first support level, and at 23.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.99, and for the 2nd resistance point, it is at 32.08.
Ratios To Look Out For
For context, Summit Therapeutics Inc’s Current Ratio is 10.15. Also, the Quick Ratio is 10.15, while the Cash Ratio stands at 6.06.
